Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial. için istatistikler
Toplam ziyaret
| views | |
|---|---|
| Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial. | 0 |
Aylık toplam ziyaret
| views | |
|---|---|
| Ocak 2025 | 0 |
| Şubat 2025 | 0 |
| Mart 2025 | 0 |
| Nisan 2025 | 0 |
| Mayıs 2025 | 0 |
| Haziran 2025 | 0 |
| Temmuz 2025 | 0 |
